Overview

Efficacy and Safety of BGG492 in the Treatment of Migraine

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of BGG492 used to treat migraine pain.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Treatments:
Sumatriptan